Published in Springer Semin Immunopathol on October 10, 2006
Chikungunya: a potentially emerging epidemic? PLoS Negl Trop Dis (2010) 2.05
Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine (2008) 1.87
Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood (2009) 1.75
Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis (2013) 1.63
The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest (2008) 1.59
Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. Hum Gene Ther (2009) 1.57
Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis (2011) 1.25
Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur J Immunol (2008) 1.23
Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med (2009) 1.13
Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques. Vaccine (2010) 0.98
Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". J Virol (2007) 0.96
Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. Trials (2014) 0.93
Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine (2014) 0.91
Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit. Vaccine (2010) 0.91
Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen. Vaccine (2009) 0.86
In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses. J Virol (2013) 0.81
An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo. Infect Immun (2014) 0.80
Experimental Rhodococcus equi and equine infectious anemia virus DNA vaccination in adult and neonatal horses: effect of IL-12, dose, and route. Vaccine (2007) 0.80
Immunogenicity of a novel enhanced consensus DNA vaccine encoding the leptospiral protein LipL45. Hum Vaccin Immunother (2015) 0.79
Vaccination of rhesus macaques with a vif-deleted simian immunodeficiency virus proviral DNA vaccine. Virology (2008) 0.79
Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV. Vaccine (2009) 0.78
Dendritic cells and the control of immunity. Nature (1998) 56.54
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
The dendritic cell system and its role in immunogenicity. Annu Rev Immunol (1991) 23.09
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 9.77
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 9.09
Molecular identification of a danger signal that alerts the immune system to dying cells. Nature (2003) 8.90
Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell (1988) 8.01
Natural adjuvants: endogenous activators of dendritic cells. Nat Med (1999) 7.10
Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol (2005) 6.81
Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem (2002) 6.16
Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med (2000) 5.62
Genetic immunization is a simple method for eliciting an immune response. Nature (1992) 5.30
Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov (2006) 5.19
Helping the CD8(+) T-cell response. Nat Rev Immunol (2004) 4.90
Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol (2005) 4.78
A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science (1995) 4.64
DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol (2000) 4.51
T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today (1999) 4.49
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A (1993) 4.49
Microneedles for transdermal drug delivery. Adv Drug Deliv Rev (2004) 4.37
Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science (2000) 4.03
Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med (1990) 3.73
DNA-based immunization by in vivo transfection of dendritic cells. Nat Med (1996) 3.62
A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med (2005) 3.59
Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol (2006) 3.57
Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem (1994) 3.41
Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A (1993) 3.27
Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med (2003) 3.21
Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med (1998) 2.84
Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology (2004) 2.80
Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med (2006) 2.70
Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol (2005) 2.61
Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol (2000) 2.54
Advances in vaccine adjuvants. Nat Biotechnol (1999) 2.18
Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med (1997) 2.12
Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol (2005) 2.01
In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta (1991) 2.00
Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med (2000) 1.98
In vivo electroporation for gene therapy. Hum Gene Ther (2006) 1.92
Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol (2001) 1.81
Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine (2004) 1.74
Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J Virol (2000) 1.69
Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol (2002) 1.58
SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol (2005) 1.57
Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine (2003) 1.56
DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol (2005) 1.52
Cellular protein is the source of cross-priming antigen in vivo. Proc Natl Acad Sci U S A (2004) 1.51
Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses (2005) 1.45
Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res (2004) 1.43
A role for class A scavenger receptor in dendritic cell nibbling from live cells. J Immunol (2003) 1.42
Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat Biotechnol (2001) 1.39
Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest (2004) 1.39
Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine (2002) 1.34
Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol (2004) 1.33
Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol (1998) 1.32
Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nat Biotechnol (2000) 1.29
Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol (2006) 1.28
Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model. J Immunol (2006) 1.26
Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res (2001) 1.24
Developing DNA vaccines that call to dendritic cells. J Clin Invest (2004) 1.24
DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J Virol (2000) 1.23
Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine (2005) 1.23
Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol (1998) 1.18
Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol (2004) 1.16
The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev (2004) 1.15
Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev (2004) 1.10
Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine (2005) 1.09
Cytotoxic T lymphocyte activation by cross-priming. Curr Opin Immunol (1999) 1.07
DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev (2004) 1.06
Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res (2000) 1.06
Cutting edge: novel human dendritic cell- and monocyte-attracting chemokine-like protein identified by fold recognition methods. J Immunol (2006) 1.04
Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques. Virology (2005) 1.04
Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res (2005) 1.04
Enhancement of DNA vaccine potency by electroporation in vivo. J Biotechnol (2000) 1.01
Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res (2000) 1.01
Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol (2005) 1.00
Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther (2001) 1.00
Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine (2001) 0.99
In vivo electroporation improves immune responses to DNA vaccination in sheep. Vaccine (2004) 0.98
DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. Virology (2005) 0.96
RTE and CTE mRNA export elements synergistically increase expression of unstable, Rev-dependent HIV and SIV mRNAs. Retrovirology (2006) 0.96
A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS. J Virol (2005) 0.95
Vaccination onto bare skin. Nature (1997) 0.93
Phase behavior of cationic amphiphiles and their mixtures with helper lipid influences lipoplex shape, DNA translocation, and transfection efficiency. Biophys J (2002) 0.93
Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques. Int Immunol (2005) 0.92
Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine (2005) 0.92
Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse. Vaccine (2001) 0.91
Direct transfection and activation of human cutaneous dendritic cells. Gene Ther (2001) 0.90
Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses. J Immunol (2000) 0.88
Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine (2004) 0.87
Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids. AIDS (2000) 0.87
Induction of positive cellular and humoral immune responses by a prime-boost vaccine encoded with simian immunodeficiency virus gag/pol. J Immunol (2006) 0.85
Intradermal DNA immunization by using jet-injectors in mice and monkeys. Vaccine (1999) 0.84
Anti-HBV immune responses in rhesus macaques elicited by electroporation mediated DNA vaccination. Vaccine (2005) 0.84
DermaVir, a novel HIV immunisation technology. Vaccine (2005) 0.83
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
Chikungunya: a potentially emerging epidemic? PLoS Negl Trop Dis (2010) 2.05
Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol (2005) 2.01
Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine (2007) 1.88
Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine (2008) 1.87
Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One (2008) 1.80
Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol (2009) 1.77
Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood (2009) 1.75
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol (2009) 1.68
Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine (2008) 1.67
Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65
Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis (2013) 1.63
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A (2007) 1.60
Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. Hum Gene Ther (2009) 1.57
HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine (2005) 1.56
Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine (2007) 1.52
An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge. Vaccine (2012) 1.52
A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis (2011) 1.45
A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine (2005) 1.45
Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses (2005) 1.45
Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr). Cancer Biol Ther (2009) 1.44
Molecular genetic relationship of the 3' untranslated region among Thai dengue-3 virus, Bangkok isolates, during 1973-2000. DNA Cell Biol (2009) 1.42
Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther (2007) 1.40
DNA vaccines: developing new strategies to enhance immune responses. Immunol Res (2008) 1.36
HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem (2002) 1.31
Induction of inflammation by West Nile virus capsid through the caspase-9 apoptotic pathway. Emerg Infect Dis (2002) 1.30
Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther (2010) 1.28
Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine (2008) 1.28
T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS (2002) 1.27
Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis (2011) 1.25
Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One (2012) 1.25
Developing DNA vaccines that call to dendritic cells. J Clin Invest (2004) 1.24
Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res (2014) 1.23
Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur J Immunol (2008) 1.23
Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol (2008) 1.22
From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol (2006) 1.21
Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol (2013) 1.19
Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma. J Allergy Clin Immunol (2005) 1.19
Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine (2008) 1.16
Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism. J Virol (2008) 1.15
IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther (2010) 1.12
Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol (2011) 1.12
The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. Nat Cell Biol (2006) 1.12
HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int Immunol (2004) 1.11
Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev (2004) 1.10
Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine (2005) 1.09
DNA vaccines: crossing a line in the sand. Introduction to special issue. Vaccine (2008) 1.06
DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev (2004) 1.06
Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther (2013) 1.05
Host cell killing by the West Nile Virus NS2B-NS3 proteolytic complex: NS3 alone is sufficient to recruit caspase-8-based apoptotic pathway. Virology (2005) 1.05
A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine (2011) 1.04
Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine (2008) 1.04
Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol (2006) 1.03
Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo. Virology (2003) 1.03
Cytokines as adjuvants for improving anti-HIV responses. AIDS (2008) 1.03
HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice. PLoS One (2013) 1.03
Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice. Curr Mol Med (2007) 1.02
HIV-1 Nef-induced FasL induction and bystander killing requires p38 MAPK activation. Blood (2005) 1.02
Mechanism of HIV-1 viral protein R-induced apoptosis. Biochem Biophys Res Commun (2003) 1.02
Suppression of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor. AIDS (2004) 1.02
Novel SIVmac DNA vaccines encoding Env, Pol and Gag consensus proteins elicit strong cellular immune responses in cynomolgus macaques. Vaccine (2009) 1.00
DNA drugs come of age. Sci Am (2010) 0.99
Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice. Vaccine (2005) 0.99
Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected]. Mol Ther (2011) 0.98
Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets. Vaccine (2011) 0.98
Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine (2008) 0.98
Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques. Vaccine (2010) 0.98
Rhesus macaques with high levels of vaccine induced IFN-gamma producing cells better control viral set-point following challenge with SIV239. Vaccine (2005) 0.98
A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge. Vaccine (2011) 0.97
DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. Virology (2005) 0.96
Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". J Virol (2007) 0.96
High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. Vaccine (2010) 0.95
A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques. Vaccine (2003) 0.94
Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin Vaccine Immunol (2010) 0.94
IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine. Vaccine (2008) 0.94
Parameters for DNA vaccination using adaptive constant-current electroporation in mouse and pig models. Vaccine (2008) 0.93
Efficient systemic expression of bioactive IL-15 in mice upon delivery of optimized DNA expression plasmids. DNA Cell Biol (2007) 0.93
Interferons as potential adjuvants in prophylactic vaccines. Expert Opin Biol Ther (2010) 0.93
HIV-1 Vpr and anti-inflammatory activity. DNA Cell Biol (2004) 0.93
HIV-1 viral genes and mitochondrial apoptosis. Apoptosis (2008) 0.93
Long-term programming of antigen-specific immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccine. PLoS One (2011) 0.93
Initiation of antiretroviral therapy during chronic SIV infection leads to rapid reduction in viral loads and the level of T-cell immune response. J Med Primatol (2006) 0.93
Co-immunization with an optimized plasmid-encoded immune stimulatory interleukin, high-mobility group box 1 protein, results in enhanced interferon-gamma secretion by antigen-specific CD8 T cells. Immunology (2009) 0.93
Synthetic DNA vaccine strategies against persistent viral infections. Expert Rev Vaccines (2013) 0.92
Ki-67 staining for determination of rhesus macaque T cell proliferative responses ex vivo. Cytometry A (2010) 0.92
DNA vaccines for targeting bacterial infections. Expert Rev Vaccines (2010) 0.92
VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine (2010) 0.92
Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy. Vaccine (2005) 0.92
Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes. Vaccine (2009) 0.92
Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses. Hum Vaccin (2011) 0.90
Augmentation of SIV DNA vaccine-induced cellular immunity by targeting the 4-1BB costimulatory molecule. Vaccine (2008) 0.90
Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice. Vaccine (2005) 0.90
Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine. Vaccine (2011) 0.90
Co-immunization with plasmid IL-12 generates a strong T-cell memory response in mice. Vaccine (2004) 0.89